Pasireotide: a novel treatment for patients with acromegaly

References

• AsaSLBilbaoJMKovacsKHypothalamic neuronal hamartoma associated with pituitary growth hormone cell adenoma and acromegalyActa Neuropathol1980522312347445985
   PubMed Web of Science ®Google Scholar
• AsaSLScheithauerBWBilbaoJMA case for hypothalamic acromegaly: a clinicopathological study of six patients with hypothalamic gangliocytomas producing growth hormone-releasing factorJ Clin Endocrinol Metab1984587968036423659
   PubMed Web of Science ®Google Scholar
• BeckersALodishMBTrivellinGX-linked acrogigantism syndrome: clinical profile and therapeutic responsesEndocr Relat Cancer20152235336725712922
   PubMed Web of Science ®Google Scholar
• BeuschleinFStrasburgerCJSiegerstetterVAcromegaly caused by secretion of growth hormone by a non-Hodgkin’s lymphomaN Engl J Med20003421871187610861322
   PubMed Web of Science ®Google Scholar
• MelmedSEzrinCKovacsKAcromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumorN Engl J Med19853129172981107
   PubMed Web of Science ®Google Scholar
• ShimonIMelmedSGrowth hormone- and growth-hormone-releasing hormone-producing tumorsCancer Treatment and ResearchLos Angeles, CASpringer Science + Business Media1997124
   Google Scholar
• TrivellinGDalyAFFauczFRGigantism and acromegaly due to Xq26 microduplications and GPR101 mutationN Engl J Med20143712363237425470569
   PubMed Web of Science ®Google Scholar
• DalyAFRixhonMAdamCHigh prevalence of pituitary adenomas: a cross-sectional study in the province of Liège, BelgiumJ Clin Endocrinol Metab2006914769477516968795
   PubMed Web of Science ®Google Scholar
• FernandezAKaravitakiNWassJAHPrevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK)Clin Endocrinol (Oxf)20107237738219650784
   PubMed Web of Science ®Google Scholar
• HoskuldsdottirGTFjalldalSBSigurjonsdottirHAThe incidence and prevalence of acromegaly, a nationwide study from 1955 through 2013Pituitary20151880380725893613
   PubMed Web of Science ®Google Scholar
• MelmedSAcromegalyN Engl J Med20063552558257317167139
   PubMed Web of Science ®Google Scholar
• MelmedSAcromegaly pathogenesis and treatmentJ Clin Invest20091193189320219884662
   PubMed Web of Science ®Google Scholar
• MelmedSPathogenesis of pituitary tumorsNat Rev Endocrinol2011725726621423242
   PubMed Web of Science ®Google Scholar
• HoldawayIMBollandMJGambleGDA meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegalyEur J Endocrinol2008159899518524797
   PubMed Web of Science ®Google Scholar
• ReidTJPostKDBruceJNFeatures at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosedClin Endocrinol (Oxf)20107220320819473180
   PubMed Web of Science ®Google Scholar
• HoldawayIMRajasooryaRCGambleGDFactors influencing mortality in acromegalyJ Clin Endocrinol Metab20048966767414764779
   PubMed Web of Science ®Google Scholar
• McCabeJAyukJSherlockMTreatment factors that influence mortality in acromegalyNeuroendocrinology Epub2015130
   PubMed Web of Science ®Google Scholar
• AyukJClaytonRNHolderGGrowth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegalyJ Clin Endocrinol Metab2004891613161715070920
   PubMed Web of Science ®Google Scholar
• BiermaszNRPituitary gland: mortality in acromegaly reduced with multimodal therapyNat Rev Endocrinol20141070871025365921
   PubMed Web of Science ®Google Scholar
• FleseriuMAdvances in the pharmacotherapy of patients with acromegalyDiscov Med20141732933824979253
   PubMed Web of Science ®Google Scholar
• GiustinaAChansonPKleinbergDExpert consensus document: a consensus on the medical treatment of acromegalyNat Rev Endocrinol20141024324824566817
   PubMed Web of Science ®Google Scholar
• JaneJAStarkeRMElzoghbyMAEndoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcomeJ Clin Endocrinol Metab2011962732274021715544
   PubMed Web of Science ®Google Scholar
• MelmedSKleinbergDBonertVAcromegaly: assessing the disorder and navigating therapeutic options for treatmentEndocr Pract20142071725374336
   PubMed Web of Science ®Google Scholar
• AlbarelFCastinettiFMorangeIOutcome of multimodal therapy in operated acromegalic patients, a study in 115 patientsClin Endocrinol201378263270
   PubMed Web of Science ®Google Scholar
• Cuevas-RamosDCarmichaelJDCooperOA structural and functional acromegaly classificationJ Clin Endocrinol Metab201510012213125250634
   PubMed Web of Science ®Google Scholar
• MercadoMEspinosaERamirezCCurrent status and future directions of the pharmacological therapy of AcromegalyMinerva Endocrinol Epub20151020
   PubMed Web of Science ®Google Scholar
• ColaoAAuriemmaRSPivonelloRThe effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegalyPituitary Epub2015820
   Web of Science ®Google Scholar
• EspinosaERamirezCMercadoMThe multimodal treatment of acromegaly: current status and future perspectivesEndocr Metab Immune Disord Drug Targets20141416918124915854
   PubMed Web of Science ®Google Scholar
• KleinbergDLPrimary therapy for acromegaly with somatostatin analogs and a discussion of novel peptide analogsRev Endocr Metab Disord20056293715711912
   PubMed Web of Science ®Google Scholar
• US Food Drug AdministrationFDA Approves Signifor, a New Orphan Drug for Cushing’s Disease2012 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332351.htmAccessed July 17, 2015
   Google Scholar
• Novartis PharmaceuticalsSignifor LAR Prescribing Information2014 Available from: http://www.pharma.us.novartis.com/product/pi/pdf/signifor_lar.pdfAccessed March 14, 2015
   Google Scholar
• BondanelliMAmbrosioMRdegli UbertiECPathogenesis and prevalence of hypertension in acromegalyPituitary2001423924912501974
   PubMedGoogle Scholar
• ColaoAFeroneDMarzulloPSystemic complications of acromegaly: epidemiology, pathogenesis, and managementEndocr Rev20042510215214769829
   PubMed Web of Science ®Google Scholar
• GurnellMPowlsonASCardiovascular disease and sleep disordered breathing in acromegalyNeuroendocrinology Epub2015728
   PubMed Web of Science ®Google Scholar
• MelmedSAcromegaly and cancer: not a problem?J Clin Endocrinol Metab2001862929293411443145
   PubMed Web of Science ®Google Scholar
• OrmeSMMcNallyRJQCartwrightRAMortality and cancer incidence in acromegaly: a retrospective cohort study 1J Clin Endocrinol Metab199883273027349709939
   PubMed Web of Science ®Google Scholar
• MestronAWebbSAstorgaREpidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA)Eur J Endocrinol200415143944615476442
   PubMed Web of Science ®Google Scholar
• LoisKBukowczanJPerrosPThe role of colonoscopic screening in acromegaly revisited: review of current literature and practice guidelinesPituitary20141856857425052731
   PubMed Web of Science ®Google Scholar
• RenehanAGBrennanBMAcromegaly, growth hormone and cancer riskBest Pract Res Clin Endocrinol Metab20082263965718971124
   PubMed Web of Science ®Google Scholar
• ColaoAPivonelloRAuriemmaRSThe association of fasting insulin concentrations and colonic neoplasms in acromegaly: a colonos-copy-based study in 210 patientsJ Clin Endocrinol Metab2007923854386017652220
   PubMed Web of Science ®Google Scholar
• LambertsSWvan der LelyAJde HerderWWOctreotideN Engl J Med19963342462548532003
   PubMed Web of Science ®Google Scholar
• Ben-ShlomoAMelmedSPituitary somatostatin receptor signalingTrends Endocrinol Metab20102112313320149677
   PubMed Web of Science ®Google Scholar
• ReubiJWaserBSchaerJ-CSomatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligandsEur J Nucl Med20012883684611504080
   PubMedGoogle Scholar
• TaboadaGFLuqueRMBastosWQuantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomasEur J Endocrinol2007156657417218727
   PubMed Web of Science ®Google Scholar
• SellersLAAldertonFCarruthersAMReceptor isoforms mediate opposing proliferative effects through gbeta gamma-activated p38 or Akt pathwaysMol Cell Biol2000205974598510913180
   PubMed Web of Science ®Google Scholar
• TheodoropoulouMStallaGKSpenglerDZAC1 target genes and pituitary tumorigenesisMol Cell Endocrinol2010326606520117169
   PubMed Web of Science ®Google Scholar
• Cuevas-RamosDFleseriuMTreatment of Cushing’s disease: a mechanistic updateJ Endocrinol2014223R19R3925134660
   PubMed Web of Science ®Google Scholar
• Ben-ShlomoAMelmedSSomatostatin agonists for treatment of acromegalyMol Cell Endocrinol200828619219818191325
   PubMed Web of Science ®Google Scholar
• KatznelsonLLawsERMelmedSAcromegaly: an endocrine society clinical practice guidelineJ Clin Endocrinol Metab2014993933395125356808
   PubMed Web of Science ®Google Scholar
• BrunsCLewisIBrinerUSOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profileEur J Endocrinol200214670771611980628
   PubMed Web of Science ®Google Scholar
• HoflandLJLambertsSWJThe pathophysiological consequences of somatostatin receptor internalization and resistanceEndocr Rev200324284712588807
   PubMed Web of Science ®Google Scholar
• LescheSLehmannDNagelFDifferential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitroJ Clin Endocrinol Metab20099465466119001514
   PubMed Web of Science ®Google Scholar
• NagelFDollCPöllFStructural determinants of agonist-selective signaling at the sst 2A somatostatin receptorMol Endocrinol20112585986621330405
   PubMedGoogle Scholar
• BrzanaJYedinakCGGultekinSHGrowth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experiencePituitary20121649049823184260
   PubMed Web of Science ®Google Scholar
• GadelhaMRKasukiLKorbonitsMNovel pathway for somatostatin analogs in patients with acromegalyTrends Endocrinol Metab20132423824623270713
   PubMed Web of Science ®Google Scholar
• WildembergLENetoLVCostaDFLow somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogsJ Endocrinol Invest201336384322472799
   PubMed Web of Science ®Google Scholar
• NielsenSMellemkjærSRasmussenLMExpression of somatostatin receptors on human pituitary adenomas in vivo and ex vivoJ Endocrinol Invest20012443043711434667
   PubMed Web of Science ®Google Scholar
• RenSGTaylorJDongJFunctional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretionJ Clin Endocrinol Metab2003884239424512970293
   PubMed Web of Science ®Google Scholar
• European Medicines AgencySummary of Product Characteristics: Signifor Powder and Solvent for Suspension for Injection2014 Available from: www.ema.europa.eu/emaAccessed May 14, 2015
   Google Scholar
• PetersennSBollerslevJArafatAMPharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I studyJ Clin Pharmacol2014541308131724800725
   PubMed Web of Science ®Google Scholar
• GadelhaMRBronsteinMDBrueTPasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trialLancet Diabetes Endocrinol2014287588425260838
   PubMed Web of Science ®Google Scholar
• HorsmansYHuKRuffinMEffect of hepatic impairment on the pharmacokinetics of pasireotide (SOM230): results from a multicenter phase I studyJ Clin Pharmacol20125255255822282526
   PubMed Web of Science ®Google Scholar
• van der HoekJde HerderWWFeeldersRAA single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patientsJ Clin Endocrinol Metab20048963864514764775
   PubMed Web of Science ®Google Scholar
• PetersennSSchopohlJBarkanAPasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trialJ Clin Endocrinol Metab2010952781278920410233
   PubMed Web of Science ®Google Scholar
• ColaoABronsteinMDFredaPPasireotide versus octreotide in acromegaly: a head-to-head superiority studyJ Clin Endocrinol Metab201499379179924423324
   PubMed Web of Science ®Google Scholar
• FleseriuMClinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature reviewPituitary20101418419321161602
   PubMed Web of Science ®Google Scholar
• van der LelyAJBillerBMKBrueTLong-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDYJ Clin Endocrinol Metab2012971589159722362824
   PubMed Web of Science ®Google Scholar
• SheppardMBronsteinMDFredaPPasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, phase III studyPituitary20141838539425103549
   PubMed Web of Science ®Google Scholar
• FleseriuMSheppardMBronsteinMDSwitching patients with acromegaly from octreotide LAR to pasireotide LAR improves biochemical control: crossover extension to a randomized, double-blind, multicenter, phase III studyThe Endocrine Society’s 94th Annual Meeting and Expo; June 23–26, 2012, Presentation Number: SUN-741Houston, TX, 2012
   Google Scholar
• FredaPUFleseriuMAJvdLImprovement of biochemical control in patients with acromegaly switched from octreotide LAR to pasireotide LAR: crossover extension to a double-blind, multicenter, randomized, phase III studyThe Endocrine Society’s 95th Annual Meeting and Expo; June 15–18, 2013, Poster Board SUN-95San Francisco, CA2013
   Google Scholar
• FleseriuMGadelhaMBronsteinMDOR7-7: pasireotide LAR provides superior efficacy over octreotide LAR and lanreotide ATG in patients with inadequately controlled acromegaly: a phase III, multi-center, randomized study (PAOLA)Growth Horm IGF Res201424S20S21
   Google Scholar
• GadelhaMRBronsteinMDBrueTBiochemical control is maintained with pasireotide LAR in patients with acromegaly: results from the extension of a randomized phase III study (PAOLA)The Endocrine Society’s 97th Annual Meeting and ExpoMar 5–8, 2015 Presentation Number: PP09-01San Diego, CA2015
   Google Scholar
• ShenoudaMMaldonadoMWangYAn open-label dose-escalation study of once-daily and twice-daily pasireotide in healthy volunteersAm J Ther20142116417322713526
   PubMed Web of Science ®Google Scholar
• HenryRRCiaraldiTPArmstrongDHyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteersJ Clin Endocrinol Metab2013983446345323733372
   PubMed Web of Science ®Google Scholar
• BreitschaftAHuKHermosillo ReséndizKManagement of hyperglycemia associated with pasireotide (SOM230): healthy volunteer studyDiabetes Res Clin Pract201410345846524461109
   PubMed Web of Science ®Google Scholar
• ColaoAMGuFGadelhaMRMetformin-based oral antidiabetic therapy proved effective in hyperglycaemia associated with pasireotide in patients with acromegalyEndocr Abstr201537E800
   Google Scholar
• GadelhaMRBrueTFleseriuMProactive monitoring and early intervention in the management of pasireotide-induced hyperglycemia: lessons from the phase III, 24-week paola studyThe Endocrine Society’s 97th Annual Meeting and ExpoMar 5–8, 2015 Presentation Number: LBT-079San Diego, CA2015
   Google Scholar
• FleseriuMHoffmanARKatznelsonLAmerican Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: management of acromegaly patients: what is the role of pre-operative medical therapy?Endocr Pract20152166867326135961
   PubMed Web of Science ®Google Scholar
• FleseriuMThe role of combination medical therapy in acromegalyCurr Opin Endocrinol Diabetes Obes201320432132923807604
   PubMedGoogle Scholar
• Ben-ShlomoAPharmacotherapy for acromegalyEndocrinol Metab Clin North Am201544354125732640
   PubMed Web of Science ®Google Scholar
• SchmidHBrueTColaoAEffect of pasireotide on GH, IGF1, IGFBP2, IGFBP3, HbA1C and glucose in patients with inadequately controlled acromegaly: exploratory results from a multicentre, randomized, 24-week study (PAOLA)Endocr Abstr201435905
   Google Scholar
• ColaoADe BlockCGaztambideMSManaging hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendationsPituitary20131718018623564338
   PubMed Web of Science ®Google Scholar
• McKeageKPasireotide in acromegaly: a reviewDrugs2015751039104826017304
   PubMed Web of Science ®Google Scholar
• TuviaSAtsmonJTeichmanSLOral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppressionJ Clin Endocrinol Metab2012972362236922539587
   PubMed Web of Science ®Google Scholar
• MelmedSPopovicVBidlingmaierMSafety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trialJ Clin Endocrinol Metab20151001699170825664604
   PubMed Web of Science ®Google Scholar
• RobertsJLindenMCervinCOctreotide fluid crystal provides sustained octreotide bioavailability and similar IGF1 suppression to that of octreotide LAR (Sandostatin LAR): randomized, open-label, Phase I, repeat-dose study in healthy volunteersEndocr Abstr201435914
   Google Scholar
• ChieffoCCookDXiangQEfficacy and safety of an octreotide implant in the treatment of patients with acromegalyJ Clin Endocrinol Metab2013984047405423969184
   PubMed Web of Science ®Google Scholar
• StörmannSSchopohlJEmerging drugs for acromegalyExpert Opin Emerg Drugs201419799724400774
   PubMed Web of Science ®Google Scholar
• PlockingerUHoffmannUGeeseMDG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumoursEur J Endocrinol201116622323422065857
   PubMed Web of Science ®Google Scholar
• SommEBonnetNMartinezAA botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axisJ Clin Invest20121223295330622850878
   PubMed Web of Science ®Google Scholar
• GarciaEATrivellinGAfloreiEDCharacterization of SNARE proteins in human pituitary adenomas: targeted secretion inhibitors as a new strategy for the treatment of acromegaly?J Clin Endocrinol Metab201398E1918E192624152687
   PubMed Web of Science ®Google Scholar
• Cuevas-RamosDFleseriuMSomatostatin receptor ligands and resistance to treatment in pituitary adenomasJ Mol Endocrinol201452R223R24024647046
   PubMed Web of Science ®Google Scholar